SCHEMBL6497461

SCHEMBL6497461

CCCCCOc1ccc(Cn2c(C)nc3ccc(OCCCC(=O)OCC)cc32)c(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.49
PDE3B Q13370 1/20 0.46
PDE3A Q14432 1/20 0.46
P2RY12 Q9H244 1/20 0.46
PLA2G2A P14555 3/20 0.43
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HSD17B10 Q99714 2/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
CYSLTR2 Q9NS75 3/20 0.42
CYSLTR1 Q9Y271 3/20 0.42
P2RX3 P56373 1/20 0.41
ALOX5AP P20292 2/20 0.40
BRD4 O60885 1/20 0.40
THRB P10828 2/20 0.39
THRA P10827 1/20 0.39
CNR2 P34972 1/20 0.39
PSEN1 P49768 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6500673 0.98 PPARG (0.49) PPARGPDE3BPDE3AP2RY12PLA2G2A
SCHEMBL6487701 0.97 PPARG (0.49) PPARGPDE3BPDE3AP2RY12PLA2G2A
SCHEMBL6498632 0.94 PDE3B (0.48) PPARGPDE3BPDE3AP2RY12PLA2G2A
SCHEMBL6497754 0.93 PDE3B (0.44) PPARGPDE3BPDE3AP2RY12PLA2G2A
SCHEMBL6495068 0.92 PPARG (0.52) PPARGPDE3BPDE3AP2RY12PLA2G2A
SCHEMBL6492145 0.91 PPARG (0.51) PPARGPDE3BPDE3AP2RY12PLA2G2A
SCHEMBL6488948 0.90 PPARG (0.43) PPARGPDE3BPDE3AP2RY12PLA2G2A
SCHEMBL6498744 0.89 PPARG (0.51) PPARGPDE3BPDE3AP2RY12PLA2G2A
SCHEMBL6491422 0.89 PPARG (0.51) PPARGPDE3BPDE3AP2RY12PLA2G2A
SCHEMBL6487942 0.89 MCL1 (0.42) PPARGPDE3BPDE3AP2RY12PLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD PPARG 233/4885PDE3B 411/4885PDE3A 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.